Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to explore the efficacy and safety of surufatinib combined with
camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG
(nab-paclitaxel and gemcitabine) in unresectable advanced or metastatic pancreatic cancer.